Dynamic News

Pharmax is supplying personal protective equipments to fight against COVID-19

2020 is an unusual year, with sudden COVID-19 quickly sweeping the globe. China have adopted strict prevention and control measures and stubbornly resisted the COVID-19. At present, the spread of the COVID-19 in China has been effectively controlled. The factory has resumed work and production, and our lives have gradually returned to normal.

We are always concerned about the development of the global epidemic. As an international company, we hope to contribute to the people who are suffering from the epidemic in the world.
Pharmax supplies the following qualified products to the global market, which are produced by the leading manufacturer in China with CE certificate available.
Medical masks N95, KN95, 3M, disposable medical masks, disposable civilian masks; medical isolating masks; medical goggles; medical protective clothing; medical protective gowns; medical non-contact thermometers; nitrile gloves;

If you are looking for these products, please feel free to contact us. We will provide you with the best supplies and services!
Contact Person: Gerry Tian
Emai: gerryt@pharmaxus.com

  Apr 03, 2020   Dynamic News   Read More

CPHI Frankfurt 2019 – Our 20th Time To Attend The World Largest Exhibition For Pharmaceutical Industry

Pharmax as an Exhibitor had just finished its 20th show at CPHI Worldwide in Frankfurt, with more than 200 visitors from over 40 countries visited us this year, we would like to thank all of our associated customers, friends from the industry for visiting us for friendship and partnership,which bring alot of exciting opportunities.
Pharmax will continue our best support and services to provide the complete strategic sourcing solution for our customers.
We care about healthier lives, and we are here to help every step of the way.

  Nov 22, 2019   Dynamic News   Read More

New Milestone – Moxidectin NDA has received approval of US FDA

We are proud to announce that our Moxidectin project has achieved a new milestone:
The New Drug Application (NDA) of Moxidectin for treatment of the orphan disease river blindness has been approved by the US FDA this week. The product was developed by Medicines Development for Global Health, an independently funded biopharmaceutical company that focuses exclusively on neglected diseases, while the Moxidectin API is supplied by Pharmax and manufactured by Livzon Group. The successful approval of the New Drug Application represents a joint success of MDGH, Pharmax and Livzon who have been working hard together for years, and the first approval of moxidectin for use in humans.
MDGH received funding for this project from the Global Health Investment Fund, and plans to supply Moxidectin to those in need, mainly in Africa. We believe the new moxidectin product will bring health benefits to people in both developing and developed world.

  Jul 24, 2018   Dynamic News   Read More

Pharmax Assisted Chongqing Southwest No.2 Pharmaceutical Factory Co., Ltd. to Pass the FDA Flight Inspection

On April 20, 2017, an inspection notification was received from Chinese office of FDA (United States Food and Drug Administration) by our company. It stated that FDA would perform an on-site inspection to Southwest No.2 Pharmaceutical Factory Co., Ltd. on April 25-28. Under the time pressure, our company quickly communicated with the factory and organized an audit team. A timely and effective improvement for the factory’s quality system was made, all the quality risks were controlled in a short time, a perfect plan for this audit was properly established. Through our company’s hard work and the factory’s active preparation, we passed this flight inspection successfully.

  Jan 25, 2018   Dynamic News   Read More